Direct thrombin inhibitors are in focus of interest for hereditary or acquired thrombophilic indications. Besides thrombosis prophylaxis in surgery, life-threatening cardiac diseases and stroke are of special interest for this new drug class. For long-term prophylaxis of genetically caused